Targeting the WNT signaling pathway represents a promising strategy for cancer therapy. The field has evolved to include numerous inhibitors currently under preclinical and clinical investigation.

New research has identified a protein that could serve as both a biomarker and therapeutic target to weaken stem-like cancer ...

Druggable phosphatases in cancer and immune cells, with examples of their corresponding drugs. Structures of allosteric inhibitors targeting PP2A, PRL3, DUSP1/6, and SHP2 in cancer cells (left).

Children with lesions on the top or back of the tongue often face significant challenges with eating and speaking. With ...

Structural insight into KRAS conformational cycling exposed temporary binding opportunities, overturning the “undruggable” ...

Scientists at The Wistar Institute and ChristianaCare’s Helen F. Graham Cancer Center & Research Institute have uncovered a ...

Scientists at The Wistar Institute and clinical researchers from ChristianaCare’s Helen F. Graham Cancer Center & Research ...

JCO Precision Oncology Conversations features discussions with leading authors of JCO Precision Oncology articles, hosted by Dr. Abdul Rafeh Naqash. Join our experts in engaging conversations as they ...

Colorectal tumors that underwent somatic next-generation sequencing (NGS) for 154-168 genes in an in-house laboratory between 2015 and 2022 were retrospectively identified. Microsatellite instability ...

Beyond weight loss, GLP-1s may offer a "two-for-one" benefit by protecting heart health, which is the leading cause of ...

Lifestyle and chemical exposures-from diet to pesticides, herbicides-are increasingly linked to rising colon cancer rates in ...